An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB
- 26 Sep 2019 Planned End Date changed from 1 Jul 2022 to 1 Jun 2021.
- 26 Sep 2019 Planned primary completion date changed from 1 Jun 2022 to 1 May 2021.
- 02 Aug 2019 Status changed from recruiting to active, no longer recruiting.